Urinary neuro-biogenic amines provide an overall assessment of a patient's ability to synthesize and metabolize neurotransmitters, both in the periphery and, for some enzymes, behind the blood brain barrier as well. Alterations in urinary neurotransmitter status may be associated with a variety of conditions including metabolic disorders, mood/behavioural disorders, and in rare occasions the presence of certain tumors. Associations between urinary neurotransmitter levels and health conditions have been documented in scientific literature and may provide valuable insights as part of a comprehensive health assessment.
This test is useful for
- Functional testing for COMT and MAOA
- Identifying neurological imbalances
- Measuring response to therapy
- Risk assessment
Analysis of urinary neuro-biogenic amines (neurotransmitters), and
their metabolites, provides a non-invasive assessment of neurotransmitter
metabolism. Neurotransmitter testing may provide therapeutic opportunities that
improve clinical success and patient health outcomes.
A review of the current scientific literature demonstrates how urinary neuro-biogenic amine testing may be used in clinical practice:
- Functional testing - Neuro-biogenic amine metabolism may be mediated by a variety of enzymes, including catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). Patterns of neurotransmitters and their metabolites may provide functional information about these two important enzymes.
- Identify imbalances - research indicates that urinary neuro-biogenic amine measurements may correlate with neurological conditions such as depression and PTSD.
- Response to therapy - certain neuro-biogenic amines, such as serotonin, may be altered by the addition of neurotransmitter precursors such as 5-hydroxytryptophan (5-HTP). These changes may be apparent in the urine.
- Risk assessment - Changes in urinary serotonin, dopamine, and glutamate levels have been suggested as biomarkers for neurobehavioral toxicology (symptoms from chemical or toxicant element environmental exposures).
Urinary levels of neuro-biogenic
amines primarily reflect the activity of the peripheral and gastrointestinal
tract enteric nervous systems. Up to 20% of urinary neurotransmitters are
estimated to originate in the central nervous system.
A lack of nutritional cofactors (vitamins, minerals) required for normal enzyme function may decrease enzyme function and neurotransmitter levels. Neurotransmitter receptors and metabolic enzymes may be subject to mutations and single nucleotide polymorphisms (SNPs) that may affect receptor or enzyme function. Normal neurotransmitter receptor function is also necessary for normal neurotransmitter activity. Neurotransmitter levels may be influenced by diet, lifestyle and other health conditions such as: high sodium intake, age, gender, body mass index, kidney function, environmental exposures, infection and tobacco use.
Compare Neuro-Biogenic Amines Profiles
Comprehensive Neuro-Biogenic Amines
|Catecholamine Fractionation, free: |
Epinephrine, Norepinephrine, Dopamine
|5-Hydroxyindolacetic acid (5-HIAA)||✓|
|3,4-Dihydroxyphenylacetic acid (DOPAC)||✓|
|Metanephrine Fractionation: |
Comprehensive Neuro-Biogenic Amines (HOR18)
Comprehensive Neuro-Biogenic Amines (urine)
Turn Around Time: 14 days.